Trial Profile
A Phase 1 Dose Escalation Safety Study Combining the ATR Inhibitor M6620 With Chemoradiotherapy in Oesophageal Cancer & Other Solid Cancers Using Time to Event Continual Reassessment Method
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary) ; Capecitabine (Primary) ; Cisplatin (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Malignant melanoma; Oesophageal cancer; Solid tumours; Squamous cell cancer; Thoracic neoplasms
- Focus Adverse reactions
- Acronyms CHARIOT
- 13 Sep 2022 Results (n=18) from cohort A2 reporting safety and preliminary efficacy presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results (n=16) from cohort A1 of this trial assessing feasibility of combining Berzosertib with radiation in esophageal cancer presented at the 47th European Society for Medical Oncology Congress
- 27 Apr 2022 Status changed from active, no longer recruiting to completed.